Últimas noticias sobre Tango Therapeutics (NASDAQ:TNGX) Bolsa

Tango Therapeutics

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

Tango Therapeutics Inc

Rosenblatt analyst Catharine Trebnick maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Buy and maintains $445 price target.

News

Price Target

Analyst Ratings

CYBR

Rosenblatt Maintains Buy on CyberArk Software, Maintains $445 Price Target

B of A Securities analyst Travis Steed maintains Solventum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) with a Neutral and raises the price target from $80 to $85.

SOLV

B of A Securities Maintains Neutral on Solventum, Raises Price Target to $85

Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound for the treatment of multiple sclerosis ("MS"). It is a patented New Chemical Entity ("NCE") that has a unique mechanism of action. As shown in preclinical models of MS, it can directly stabilize the myelin sheath surrounding nerve fibers and thus provide protection from demyelination. MS is a disease characterized by demyelination, a process that causes progressive disability.

QNTM

Quantum Biopharma's Lucid-21-302 Passes Phase 1 Safety Review, Advancing Toward Phase 2 In MS Treatment

Rosenblatt analyst Barton Crockett maintains Liberty Formula One Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONK#NASDAQ">FWONK</a>) with a Buy and maintains $102 price target.

FWONK

Rosenblatt Maintains Buy on Liberty Formula One Gr, Maintains $102 Price Target

PSTV

Plus Therapeutics Completes ReSPECT-LM Phase 1 Trial, Identifies Recommended Phase 2 Dose For CNS Cancer Treatment

SYTA

In Exchange For Outstanding Shares Of Core Gaming, Siyata Will Issue Common Shares To The Shareholders Of Core Gaming Based On Exchange Ratio Calculated As $160,000,000 Divided By Volume-Weighted Average Closing Price Of Siyata's Common Shares For 10-Day Trading Period Immediately Preceding Effective Time Of Merger

Lucid Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) is looking to unveil its new vehicles based on its midsize platform later this year or early next year, according to the company&#8217;s interim CEO Marc Winterhoff.
What Happened: Lucid is looking to bring three midsize vehicles to the market and the first of them is scheduled to start production in 2026, Winterhoff said.
The vehicles, he said, will be unveiled later this year or early next year. The company has completed the advanced engineering phase of two of the midsize vehicles, he said, while adding that they will now move on to the development and industrialization phase.
Both of Lucid&#8217;s current offerings &#8211; the <a href="https://www.benzinga.com/25/01/42842059/lucids-q4-deliveries-soar-to-new-highs-gravity-suv-sets-optimism-for-coming-months">Air sedan and the Gravity SUV</a>&#8211; are higher-end EVs with a high price point. While the base version of the Air sedan starts at $69,900, the only available Grand Touring variant of the Gravity starts at $94,900.
With the midsize platform, the company intends to expand its addressable market and increase delivery volumes. Lucid also intends to sell some of its midsize vehicles to the government of Saudi Arabia as part of a deal entered into in 2022.
Why It Matters: Lucid&#8217;s former CEO Peter Rawlinson has previously said that the high-volume midsize vehicle will start at around $48,000. A price point of $48,000 will put the vehicle in direct competition with Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) best-selling Model Y SUV.
It is unclear if all the three midsize vehicles that Lucid is planning will be priced in the same range. It is also not known whether the vehicle would be a sedan, SUV, or another form. 
A lower-priced sedan would also put Lucid in direct competition against Tesla&#8217;s cheapest offering, the Model 3 sedan which has a starting price of $42,490.
Lucid did not immediately respond to <a href="https://pro.benzinga.com/dashboard">Benzinga</a>&#8216;s request for comment. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43966461/lucid-to-up-production-increase-advertising-and-sell-in-saudi-arabia-to-up-high-end-gravity-suv-sales-this-year" target="_blank" rel="noreferrer noopener">Lucid Gravity Customers Opting For High-End Configurations, All The Way Up To $120,000: CEO Says SUV ‘Attracting New People To The Brand'</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

LCID

TSLA

Lucid Prepares To Launch Affordable EVs: First Midsize Model Could Be Unveiled As Early As This Year To Take On Elon Musk's Tesla

As part of the agreement, Tollo will assist Wellgistics LLC in preparing materials to market Tollo's emerging suite of products to Wellgistics LLC's network of pharmacies by generating healthcare practitioner-tailored content to help them educate client physicians, physician groups and patients on how to optimize patient outcomes by incorporating these select medical foods into patients' treatment regimens. Medical foods are specialized foods, to be taken under the supervision of a physician, that are for the dietary management of certain health conditions. Wellgistics LLC's objective of marketing Tollo's medical foods is to provide patients with the dietary support they need to get the most out of prescription drugs and other treatment modalities used by their physicians to help manage complex chronic conditions.

WGRX

Wellgistics Expands Healthcare Offerings With Tollo Health Deal, Targeting GLP-1 and Long COVID Markets

KELYA

Kelly Launches Integrated Permanent Hiring Solutions Business, Combining KellyOCG And Motion Recruitment Partners' Brands

MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.60) by 20 percent. This is a 620 percent decrease over losses of $(0.10) per share from the same period last year.

Earnings

MLTX

MoonLake Q4 2024 GAAP EPS $(0.72) Misses $(0.60) Estimate, Year-end Cash, Cash Equivalents And Short-term Marketable Debt Securities Of $448M Expected To Providing Cash Runway To At Least The End Of 2026

Siyata Mobile Signs Merger Agreement With Core Gaming; Core To Become Wholly Owned Subsidiary Of Siyata

Rosenblatt analyst Kevin Cassidy maintains Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) with a Buy and maintains $30 price target.

BTDR

Rosenblatt Maintains Buy on Bitdeer Technologies, Maintains $30 Price Target

B of A Securities analyst John Murphy downgrades Lucid Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) from Neutral to Underperform and lowers the price target from $3 to $1.

Downgrades

B of A Securities Downgrades Lucid Gr to Underperform, Lowers Price Target to $1

HC Wainwright &amp; Co. analyst Emily Bodnar upgrades Arcus Biosciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCUS#NYSE">RCUS</a>) from Neutral to Buy and announces $24 price target.

Upgrades

RCUS

HC Wainwright & Co. Upgrades Arcus Biosciences to Buy, Announces $24 Price Target

Federal Realty Expands West Coast Portfolio With $123.5M Acquisition Of Del Monte Shopping Center

REKR

Rekor Systems Launches 90-Site Study In Phoenix To Analyze Electric Vehicle Movement And Support EV Infrastructure Development

Needham analyst Chris Pierce reiterates Lucid Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Lucid Grto Hold

Shares of&nbsp;Alibaba Group Holding Ltd.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) climbed 4.3% during the pre-market trading session on Wednesday following the launch of its video-generation AI Model today. The stock also climbed on a positive analyst call.
What Happened: Bernstein, a prominent investment management firm, has upgraded Alibaba&#8217;s stock from &#8216;market perform&#8217; to &#8216;Outperform&#8217; and raised its price target by $61 to $165, CNBC <a href="https://www.cnbc.com/2025/02/26/bernstein-upgrades-alibaba-thanks-to-ai-calls-for-shares-to-rally-more-than-20percent.html">reported</a> on Wednesday. This new target indicates more than a 20% upside potential from Tuesday&#8217;s closing price.
Analyst Robin Zhu expects a continued positive sentiment around AI will fuel Alibaba&#8217;s growth. The analyst also anticipates that Alibaba&#8217;s earnings will trend upward, driven by more efficient capital allocation, a stronger AI industry structure compared to traditional cloud, and potential spillover benefits from China&#8217;s AI capital expenditure surge.
Zhu also predicts a significant increase in revenue growth for Alicloud, Alibaba&#8217;s cloud computing division, during the first two quarters of 2025.
Today, the Chinese tech giant launched its open-source video-and-image-generating artificial intelligence model Wan 2.1 amid steep competition from DeepSeek and other rivals, reported Reuters. Alibaba introduced four variants of Wan 2.1—T2V-1.3B, T2V-14B, I2V-14B-720P, and I2V-14B-480P—designed to generate images and videos from text and image inputs.
SEE ALSO: <a href="https://www.benzinga.com/markets/25/02/43903306/hugh-grant-saved-a-fortune-by-inventing-a-fictitious-agent-it-helped-him-accrue-150-million-from-act">Hugh Grant Saved A Fortune By Inventing A Fictitious Agent. It Helped Him Accrue $150 Million From Acting, Real Estate And Art</a>
Why It Matters: Alibaba&#8217;s AI advancements have been a key focus for the company. On Tuesday, the Chinese e-commerce giant showcased its <a href="https://www.benzinga.com/media/25/02/43939199/alibaba-doubles-down-on-ai-launches-qwq-max-to-challenge-openai-and-deepseek">next reasoning model, QwQ-Max</a>, which could rival industry-leading competitors, including OpenAI's o1 and DeepSeek's R1. The Qwen team announced that QwQ-Max-Preview is free on the Qwen chatbot website.
Alibaba&#8217;s shares have already experienced a 50% increase over the past month, following the impact of Chinese startup Deepseek&#8216;s low-cost, open-source model on U.S. tech stocks. This optimism also comes in the wake of the company&#8217;s strong fourth-quarter results last week, which led to a significant rise in share prices.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/02/43968607/trump-negotiates-a-very-big-deal-for-ukraines-mineral-wealth">Trump Negotiates A &#8216;Very Big Deal&#8217; For Ukraine&#8217;s Mineral Wealth, But Lacks Long-Term Security Guarantees: Report</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

WIIM

Markets

BABA

Analyst Sees 20% Upside For Alibaba On AI Breakthrough And Positive Outlook: BABA Stock Pops Over 4% In Wednesday Pre-Market

Needham analyst Joseph Stringer reiterates Vaxcyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) with a Buy and maintains $140 price target.

PCVX

Needham Reiterates Buy on Vaxcyte, Maintains $140 Price Target

MGPI

MGP Ingredients Sees FY25 Net Sales Between $520M-$540M Vs. $593.01M Estimate

Press Releases

Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Tango Therapeutics to Participate in Upcoming Investor Conferences

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences

TNGX

Abeona Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Tango Therapeutics

Noticias

Últimas noticias sobre Tango Therapeutics (NASDAQ:TNGX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL